Relationship between the levels of serum fibroblast growth factor 19 and metabolic factors in obese and normal weight subjects with and without type 2 diabetes mellitus: a case-control study
-
Hamidreza Razmi
Abstract
Objectives
Fibroblast growth factor 19 (FGF-19) is a metabolic regulating factor with an anti-diabetic effect. This study aimed to evaluate FGF-19 in patients with type 2 diabetes mellitus (T2DM) and its relationship with some metabolic risk factors.
Methods
In this case-control study, 80 diabetic patients and 80 non-diabetic individuals were divided into two subgroups based on body mass index (BMI): obese people (BMI≥30) and participants with normal weight (25>BMI≥18.5). Furthermore, stratified analysis by gender was also performed. The metabolic factors were measured and compared in all groups. The relationship between FGF-19 and the measured items was investigated in each group.
Results
The FGF-19 levels did not show a significant difference between groups. The serum levels of FGF-19 were negatively associated with some metabolic items, such as BMI, low-density lipoprotein (LDL), total cholesterol (TC) (p<0.01), and LDL/high-density lipoprotein (HDL) ratio (p=0.02) only in the healthy group with normal weight. According to the gender-based classification of individuals, FGF-19 showed a significant inverse relationship with BMI, weight (WT), waist circumference (WC), and hip circumference (HC) (p<0.05) in diabetic men; besides, FGF-19 in non-diabetic women had a significant negative association with TC, LDL, and LDL/HDL ratio (p<0.05).
Conclusions
The levels of FGF-19 were negatively correlated to WT, BMI, WC and HC in diabetic males. More studies are needed to warrant these results.
Funding source: Tabriz University of Medical Sciences
Acknowledgment
The authors thank Research Vice-chancellor of Tabriz University of Medical Science for supporting this study. This is a part of a database from MSc thesis entitled “The relationship between serum levels of fibroblast growth factor-19 (FGF-19) and lipid profile, glycemic parameters, anthropometric indices and dietary habits of patients with type 2 diabetes mellitus compared with healthy people".
Research funding: Funded by Tabriz University of Medical Sciences.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: The authors declare that they have no conflict of interest.
Informed consent: An informed written consent form was obtained from all the participants before the initiation of the study.
Ethical approval: The study protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1398.746).
References
1. Basith Khan, MA, Hashim, MJ, King, JK, Govender, RD, Mustafa, H, Kaabi, JA. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health 2020;10:107–11. https://doi.org/10.2991/jegh.k.191028.001.Search in Google Scholar
2. Farmanfarma, KK, Ansari-Moghaddam, A, Zareban, I, Adineh, H. Prevalence of type 2 diabetes in Middle–East: systematic review& meta-analysis. Prim Care Diabetes 2020;14:297–304. https://doi.org/10.1016/j.pcd.2020.01.003.Search in Google Scholar
3. Esteghamati, A, Etemad, K, Koohpayehzadeh, J, Abbasi, M, Meysamie, A, Noshad, S, et al.. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. Diabetes Res Clin Pract 2014;103:319–27. https://doi.org/10.1016/j.diabres.2013.12.034.Search in Google Scholar
4. Sarayani, A, Rashidian, A, Gholami, K. Low utilisation of diabetes medicines in Iran, despite their affordability (2000–2012): a time-series and benchmarking study. BMJ open 2014;4:58–9. https://doi.org/10.1136/bmjopen-2014-005859.Search in Google Scholar
5. Payahoo, L, Ostadrahimi, A, Mobasseri, M, Khajebishak, Y, Asghari Jafarabadi, M, Mahdavi, A, et al.. Anethum graveolens L. supplementation has anti-inflammatory effect in type 2 diabetic patients. Indian J Tradit Knowl 2014;13:461–5.Search in Google Scholar
6. Keykha, MJM, Amini, M. Prevalence and risk factors of diabetes, pre-diabetes and metabolic syndrome in first-degree relatives of patients with type ii diabetes. J Kerman Univ Med Sci 2013;20:115–28.Search in Google Scholar
7. Payahoo, L, Khajebishak, Y, Asghari Jafarabadi, M, Ostadrahimi, A. Oleoylethanolamide supplementation reduces inflammation and oxidative stress in obese people: a clinical trial. Adv Pharmaceut Bull 2018;8:479–87. https://doi.org/10.15171/apb.2018.056.Search in Google Scholar
8. Bhupathiraju, SN, Hu, FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 2016;118:1723–35. https://doi.org/10.1161/circresaha.115.306825.Search in Google Scholar
9. Kyle, TK, Dhurandhar, EJ, Allison, DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin N Am 2016;45:511–20. https://doi.org/10.1016/j.ecl.2016.04.004.Search in Google Scholar
10. Opie, CA, Haines, HM, Ervin, KE, Glenister, K, Pierce, D. Why Australia needs to define obesity as a chronic condition. BMC Publ Health 2017;17:500. https://doi.org/10.1186/s12889-017-4434-1.Search in Google Scholar
11. Kyrou, I, Randeva, HS, Tsigos, C, Kaltsas, G, Weickert, MO. Clinical problems caused by obesity. Endotext [Internet]. MDText. com, Inc.; 2018:2000 p.Search in Google Scholar
12. Mráz, M, Lacinová, Z, Kaválková, P, Haluzikova, D, Trachta, P, Drapalova, J, et al.. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. Physiol Res 2011;60:627–36. https://doi.org/10.33549/physiolres.932099.Search in Google Scholar
13. Barutcuoglu, B, Basol, G, Cakir, Y, Cetinkalp, S, Parildar, Z, Kabaroglu, C, et al.. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011;41:390–6.Search in Google Scholar
14. Owen, BM, Mangelsdorf, DJ, Kliewer, SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metabol 2015;26:22–9. https://doi.org/10.1016/j.tem.2014.10.002.Search in Google Scholar
15. Liu, Y, Yu, D, Wang, X, Tan, X, Luo, X, Fan, H, et al.. Is cerebrospinal fluid fibroblast growth factor 19 (FGF19) a mood regulator? Neuropsychiatry 2017;7:126–30.10.4172/Neuropsychiatry.1000187Search in Google Scholar
16. Marcelin, G, Jo, Y-H, Li, X, Schwartz, GJ, Zhang, Y, Dun, NJ, et al.. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 2014;3:19–28. https://doi.org/10.1016/j.molmet.2013.10.002.Search in Google Scholar
17. Angelin, B, Larsson, TE, Rudling, M. Circulating fibroblast growth factors as metabolic regulators – a critical appraisal. Cell Metabol 2012;16:693–705. https://doi.org/10.1016/j.cmet.2012.11.001.Search in Google Scholar
18. Nicholes, K, Guillet, S, Tomlinson, E, Hillan, K, Wright, B, Frantz, GD, et al.. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295–307. https://doi.org/10.1016/s0002-9440(10)61177-7.Search in Google Scholar
19. Wu, X, Ge, H, Baribault, H, Gupte, J, Weiszmann, J, Lemon, B, et al.. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res 2013;54:325–32. https://doi.org/10.1194/jlr.m027094.Search in Google Scholar
20. Perry, RJ, Lee, S, Ma, L, Zhang, D, Schlessinger, J, Shulman, GI. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nut commun 2015;6:6980. https://doi.org/10.1038/ncomms7980.Search in Google Scholar
21. Morton, GJ, Matsen, ME, Bracy, DP, Meek, TH, Nguyen, HT, Stefanovski, D, et al.. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 2013;123:4799–808. https://doi.org/10.1172/jci70710.Search in Google Scholar
22. Bozadjieva, N, Heppner, KM, Seeley, RJ. Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery. Diabetes 2018;67:1720–8. https://doi.org/10.2337/dbi17-0007.Search in Google Scholar
23. Roesch, SL, Styer, AM, Wood, GC, Kosak, Z, Seiler, J, Benotti, P, et al.. Perturbations of fibroblast growth factors 19 and 21 in type 2 diabetes. PloS One 2015;10:1–12. https://doi.org/10.1371/journal.pone.0116928.Search in Google Scholar
24. Mirmiran, P, Esfahani, FH, Mehrabi, Y, Hedayati, M, Azizi, F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Publ Health Nutr 2010;13:654–62. https://doi.org/10.1017/s1368980009991698.Search in Google Scholar
25. Stanley, S, Buettner, C. FGF19: how gut talks to brain to keep your sugar down. Mol Metab 2013;3:3–4. https://doi.org/10.1016/j.molmet.2013.10.008.Search in Google Scholar
26. Fang, Q, Li, H, Song, Q, Yang, W, Hou, X, Ma, X, et al.. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 2013;36:2810–4. https://doi.org/10.2337/dc12-1766.Search in Google Scholar
27. Gómez-Ambrosi, J, Gallego-Escuredo, JM, Catalán, V, Rodríguez, A, Domingo, P, Moncada, R, et al.. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet-or surgically-induced weight loss. Clin Nutr 2017;36:861–8. https://doi.org/10.1016/j.clnu.2016.04.027.Search in Google Scholar
28. Gallego-Escuredo, JM, Gómez-Ambrosi, J, V Catalan, V, Domingo, P, Giralt, M, Frühbeck, G, et al.. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes 2014;39:1–9. https://doi.org/10.1038/ijo.2014.76.Search in Google Scholar
29. Zhou, M, Luo, J, Chen, M, Yang, H, Learned, RM, DePaoli, AM, et al.. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J Hepatol 2017;66:1182–92. https://doi.org/10.1016/j.jhep.2017.01.027.Search in Google Scholar
30. Tomlinson, E, Fu, L, John, L, Hultgren, B, Huang, X, Renz, M, et al.. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741–7. https://doi.org/10.1210/endo.143.5.8850.Search in Google Scholar
31. Antonellis, PJ, Droz, BA, Cosgrove, R, O’Farrell, LS, Coskun, T, Perfield, JW, et al.. The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis. Mol Metab 2019;30:131–9. https://doi.org/10.1016/j.molmet.2019.09.006.Search in Google Scholar
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/hmbci-2020-0075).
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Letter to the Editor
- Kerala model for combating COVID-19 pandemic
- Original Articles
- Evaluation of the potential anticancer activity of different vitamin D metabolites on colorectal and breast cancer cell lines
- Relationship between the levels of serum fibroblast growth factor 19 and metabolic factors in obese and normal weight subjects with and without type 2 diabetes mellitus: a case-control study
- Early-life stress altered pancreatic Krebs cycle-related enzyme activities in response to young adulthood physical and psychological stress in male rat offspring
- Effect of short-term and long-term traffic noise exposure on the thyroid gland in adult rats: a sexual dimorphic study
- The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats
- Comparison of the effects of zinc oxide and zinc oxide nanoparticles on the expression of hepcidin gene in rat liver
- Comparison between Iberet Folic® and Zincofer® in treatment of iron deficiency anaemia in pregnancy
- Mini Review
- COVID-19 and pregnancy: are they friends or enemies?
- Review Articles
- COVID-19: a review on SARS-CoV-2 origin, epidemiology, virology, clinical manifestations and complications with special emphasis on adverse outcome in Bhopal Gas Tragedy survivor
- COVID-19 and neurology perspective
- COVID-19 and nutritional deficiency: a review of existing knowledge
- COVID-19 and geriatric population: from pathophysiology to clinical perspectives
- COVID-19 and cardiovascular disease: a review of current knowledge
- How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?
Articles in the same Issue
- Frontmatter
- Letter to the Editor
- Kerala model for combating COVID-19 pandemic
- Original Articles
- Evaluation of the potential anticancer activity of different vitamin D metabolites on colorectal and breast cancer cell lines
- Relationship between the levels of serum fibroblast growth factor 19 and metabolic factors in obese and normal weight subjects with and without type 2 diabetes mellitus: a case-control study
- Early-life stress altered pancreatic Krebs cycle-related enzyme activities in response to young adulthood physical and psychological stress in male rat offspring
- Effect of short-term and long-term traffic noise exposure on the thyroid gland in adult rats: a sexual dimorphic study
- The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats
- Comparison of the effects of zinc oxide and zinc oxide nanoparticles on the expression of hepcidin gene in rat liver
- Comparison between Iberet Folic® and Zincofer® in treatment of iron deficiency anaemia in pregnancy
- Mini Review
- COVID-19 and pregnancy: are they friends or enemies?
- Review Articles
- COVID-19: a review on SARS-CoV-2 origin, epidemiology, virology, clinical manifestations and complications with special emphasis on adverse outcome in Bhopal Gas Tragedy survivor
- COVID-19 and neurology perspective
- COVID-19 and nutritional deficiency: a review of existing knowledge
- COVID-19 and geriatric population: from pathophysiology to clinical perspectives
- COVID-19 and cardiovascular disease: a review of current knowledge
- How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?
